Albrecht Läufer has over 35 years of international management experience in the pharmaceutical, vaccine and chemical industries. His Corvay group of companies is active in consulting and trade as well as biotech process development in Hannover and in Cologne.  He is co-founder and Managing Director of BluCon Biotech GmbH, Cologne.
Albert Läufer assumed duties as the CEO of AYOXXA in November 2021.

China-Representative, GHA – German Health Alliance
Co-Founder / Partner 1st EC Investment
Involved in the government level cooperation between Germany and China in medical economy and biotechnology and has gained solid experience as a serial entrepreneur in cross border projects.

Markus Zumbansen drives our product development with more than 15 years of experience designing, planning, and building platform technologies consisting of a device, consumables, and biochemical reagents. After receiving his PhD in Biochemistry from the University of Cologne for research in neurobiology and signal transduction, he held different R&D positions at amaxa Biosystems (now Lonza) and Miltenyi Biotec.

Experienced Financial Manager with 25+ years of experience in financial management of corporate and start-up companies, as well as in the venture capital industry. He managed a number of transactions in the field of equity and mezzanine financing, as well as various exits, including an IPO on Nasdaq.

Several years of experience in different Quality Assurance and Regulatory Affairs roles in Thermo Fisher Scientic, Abbott Diagnostics, Agilent and others

Several years of experience in different Quality Assurance and Regulatory Affairs roles in Thermo Fisher Scientic, Abbott Diagnostics, Agilent and others